Drug intelligence / Profile preview

smeitinib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Smeitinib is an orally administered small molecule that acts as a MEK1/2 inhibitor. It is currently under investigation for the treatment of Type I Neurofibromatosis (NF1), a genetic disorder characterized by tumor growth in the nervous system. By selectively binding to and blocking the mitogen-activated protein kinase (MEK) 1/2 protein, smeitinib aims to inhibit the MEK/ERK signaling pathway, which plays a crucial role in cell growth and proliferation, thereby inducing tumor shrinkage. This approach is being explored to improve surgical outcomes and reduce tumor recurrence in NF1 patients.

Other names: Smeitinib hydrosulfate capsules口服硫酸氢司美替尼胶囊

Targets

MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on smeitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on smeitinib.

Explore the full profile